首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1622103

全球冷凍足部治療市場規模（按產品類型、應用、地區、範圍和預測）

Global Freezing Of Gait Treatment Market Size By Product Type (Carbidopa/Levodopa, Deep Brain Stimulation, Wearable and Walking Aid Devices), By Application (Hospitals, Clinics), By Geographic Scope And Forecast

出版日期: 2024年07月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

凍腿治療的市場規模及預測

近年來，凍結步態治療市場規模一直以顯著的速度快速增長，預計在市場估計和預測期（2021-2028 年）內將顯著增長。

帕金森病患病率的不斷上升推動了步態凍結治療市場的成長。市場進行了全面評估市場。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

全球冷凍足治療市場的定義

步態凍結（FOG）通常被認為是帕金森氏症的多巴胺抵抗運動症狀之一。帕金森氏症是第二常見的神經退化性疾病，影響約 1% 的 60 歲或以上成年人。在85歲以上的人群中，發病率上升至3%至5%。心跳過慢、靜止性震顫、僵硬和姿勢反射消失是最常見的症狀。隨著病情的進展，大多數 PD 患者失去姿勢反射，導致步態和平衡問題。

彎腰駝背、步態凍結 (FOG)、蹲伏和跌倒都是 PD 中常見的步態障礙。 FOG 被定義為無法解釋地無法啟動有效步伐的情況，最常見的是在面臨障礙物、門口、壓力或乾擾時啟動和轉身時出現。最近的研究表明，左旋多巴 (L-dopa) 或恩他卡朋治療可以改善非相關性 FOG。左旋多巴已被證明可以減少 FOG 發作的持續時間和頻率。與 ON 相關的 FOG 很少見且難以診斷。與許多其他疾病一樣，FOG 只有在晚期才會對治療產生抗藥性。

迄今為止，左旋多巴是帕金森氏症的黃金標準治療。左旋多巴顯著改善運動症狀。與安慰劑或低劑量左旋多巴相比，高劑量左旋多巴可以延緩和減少 FOG 的發作。左旋多巴顯著減少了運動不能和眼球震顫發作的次數。左旋多巴還可以減少與 "關" 相關的霧化昏迷的頻率和持續時間。深部腦部刺激 (DBS) 已被證明可以改善 FOG 並減少 FOG 的跌倒。

冷凍足部治療的全球市場概況

帕金森氏症患者病率的不斷上升正在推動步態凍結治療市場的成長。步態凍結是帕金森氏症和其他帕金森氏症的常見症狀。步態凍結常常導致跌倒、隨後的受傷以及喪失獨立性，給患者及其家人帶來沉重的負擔。步態僵硬的治療涉及全面的病理生理學，包括其陣發性和多變性、運動（步行機制受損）和非運動（認知障礙、焦慮）障礙的相互作用以及多種神經元連接障礙。各種原因，治療起來很困難因素，包括複雜（並且可能是異質的）的潛在神經基質。由於該病症與帕金森氏症有關，預計市場將出現健康成長。

全球老年人口的成長是市場發展的最大動力。根據一項研究顯示，每年約有6萬名北美人被診斷出患有帕金森氏症，因此北美市場潛力巨大。此外，研究發現，男性比女性更容易罹患此類疾病。老年人不僅更容易生病，更容易患上各種慢性和潛在致命的疾病，更容易患上導致終身疼痛的疾病，例如脊椎痛和關節痛。然而，部分患者服用步態凍結相關藥物後可能會出現副作用，這可能會抑制步態凍結治療市場的成長。

Increasing prevalence of Parkinson's disease driving the growth of the Freezing Of Gait Treatment Market. The growing geriatric population worldwide is the biggest driver of the Freezing Of Gait Treatment Market. The Global Freezing Of Gait Treatment Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Freezing Of Gait Treatment Market Definition

Freezing of gait (FOG) is frequently regarded as one of the dopamine-resistant motor symptoms of Parkinsonism. Parkinson's disease is the second most prevalent neurodegenerative disorder, impacting about 1% of adults over 60 years of age. In persons above the age of 85, the incidence rises from 3% to 5%. Bradykinesia, resting tremor, rigidity, and lack of postural reflexes are the most common symptoms. As the disease progresses, most people with PD lose their postural reflexes, leading to walking difficulties and balance problems.

Stooped posture, freezing of gait (FOG) festination, shuffling steps, and falling are all common PD gait disorders. FOG, defined as an onset of inability to start effective steps without a known cause, is most particularly experienced during step initiation and turning, especially facing obstacles, doorways, stress, and distraction. Treatment with levodopa (L-dopa) or entacapone has been shown to improve Off-related FOG in recent studies. L-dopa has been shown to reduce the duration and frequency of FOG episodes. On-related FOGs are uncommon and difficult to diagnose. FOGs, like many other symptoms, are only resistant to treatment at the most advanced stages of the disease.

To date, Levodopa is the gold standard for Parkinson's disease treatment. Levodopa can considerably improve the symptoms of movement. High-dose levodopa can delay and reduce the occurrence of FOG when compared to placebo or low-dose levodopa. Levodopa can significantly decrease the number of episodes of akinesia and FOG. Levodopa can also reduce the frequency and duration of 'off'-related FOG. Deep brain stimulation (DBS) has been shown to improve FOG and reduce falls in FOG.

Global Freezing Of Gait Treatment Market Overview

Increasing prevalence of Parkinson's disease driving the growth of the Freezing Of Gait Treatment Market. Freezing of gait is a common symptom of Parkinson's syndrome and several other forms of parkinsonism. Freezing is a major burden for both patients and families since it often leads to falls, injuries from falls, and a loss of independence. Treatment of gait freezing is difficult due to a variety of factors, including its paroxysmal and changeable nature; comprehensive pathophysiology encompassing an interplay among motor (disturbed stepping mechanisms) and non-motor (cognitive decline, anxiety); and a complex (and likely heterogeneous) fundamental neural substrate, which includes multiple failing neural connections. As the disease is correlated with Parkinson's disease, the market is expected to grow healthy.

The growing geriatric population worldwide is the biggest driver of the market. According to a study, around 60,000 Americans are diagnosed with Parkinson's disease every year, therefore the market in North America has a lot of potential. Furthermore, it has been discovered that men are more vulnerable to developing such diseases than women. The rise in the geriatric population is also benefitting the Freezing Of Gait Treatment Market, since older people are more likely to become ill and suffer a variety of chronic or fatal diseases, as well as disorders that cause them pain throughout their life, such as spinal or joint pain. However, some patients develop side effects after taking medications related to the freezing of gait which might restrain the Freezing Of Gait Treatment Market growth.

Global Freezing Of Gait Treatment Market: Segmentation Analysis

The Global Freezing Of Gait Treatment Market is segmented on the basis of Product Type, Application, And Geography.

Freezing Of Gait Treatment Market, By Product Type

Carbidopa/Levodopa
Deep Brain Stimulation
Wearable and Walking Aid Devices

Based on Product Type, The market is segmented into Carbidopa/Levodopa, Deep Brain Stimulation, and Wearable and Walking Aid Devices. Carbidopa/Levodopa segment is expected to grow at a significant rate during forecasted years. To date, Levodopa is the gold standard for Parkinson's disease treatment. Levodopa can significantly decrease the number of episodes of akinesia and FOG.

Freezing Of Gait Treatment Market, By Application

Hospitals
Clinics
Others

Based on Application, The market is segmented into Hospitals, Clinics, and Others. The Hospitals segment is expected to grow at a significant rate during the forecasted years. This is owing to, symptomatic and neuroprotective therapies being preferred in Hospitals, according to FDA and other research studies.

Freezing Of Gait Treatment Market, By Geography

North America
Europe
Asia Pacific
Rest of the world
On the basis of Geography, The Global Freezing Of Gait Treatment Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Owing to the increased frequency of Parkinson's disease in North America especially the United States generated the highest revenue share in the Freezing Of Gait Treatment Market. Rising awareness of new medications and therapies, FDA approvals for new drugs, and an expansion in PD care services, as well as an improved reimbursement structure, will fuel demand in the near future.

Key Players

The "Global Freezing Of Gait Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Acorda Therapeutics, Teva Pharmaceuticals, GYENNO, MedEXO Robotics, APDM, INC.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

In November 2020: MedEXO Robotics is a Hong Kong-based robotics technology company that recently launched the ExoBeam walking device to help people with Parkinson's disease and other movement disorders. For continuous monitoring, the ExoBeam system consists of a small laser projector that can be attached to the wearer's pants, belt, or cane.
In January 2018: GYENNO, a Chinese firm that develops technologies to help people with Parkinson's disease and other movement disorders, was showing off its Gait Aid Equipment package at the recent CES 2018 conference in Las Vegas.

1 INTRODUCTION OF GLOBAL FREEZING OF GAIT TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL FREEZING OF GAIT TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY PRODUCT TYPE

5.1 Overview
5.2 Carbidopa/Levodopa
5.3 Deep Brain Stimulation
5.4 Wearable and Walking Aid Devices

6 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY APPLICATION

6.1 Overview
6.2 Hospitals
6.3 Clinics
6.4 Others

7 GLOBAL FREEZING OF GAIT TREATMENT MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East and Africa

8 GLOBAL FREEZING OF GAIT TREATMENT MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Acorda Therapeutics
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Teva Pharmaceuticals
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 GYENNO
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 MedEXO Robotics
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 APDM, INC
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments